arrow
E

Emma Zattarin

università di modena e reggio emilia
H指数:16
被引数:981

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort study

BRCA1与BRCA2致病变异或可能致病变异女性中糖耐量受损的比较:一项前瞻性队列研究的结果

2026-05-140
OA
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

BRCA突变HR阳性/HER2阴性晚期乳腺癌在接受CDK4/6抑制剂治疗后使用PARP抑制剂的实效性

2025-12-130
OAAI
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

停用免疫检查点抑制剂的晚期实体瘤患者的结局: 系统回顾和荟萃分析

2024-07-010
OAAI
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors

外周血淋巴细胞预测接受CDK4/6抑制剂治疗的激素受体阳性HER2-negative晚期乳腺癌患者的临床结局

2023-12-201
OAAI
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities
2023-10-013
PRE
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023-04-1715
OAAI
The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
2023-04-1310
OAAI
HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy
2023-03-013
PRE
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy

中性粒细胞与淋巴细胞比值和EPSILoN评分在接受一线化疗免疫治疗的晚期非小细胞肺癌患者中的预后作用

2022-06-204
PRE
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
2022-04-0145
OAAI
Evaluation of COVID-19 impact on DELAYing diagnostictherapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario (vol 7, 100406, 2022)
2022-04-012
OAAI